Biocon Secures USFDA Approval for Liraglutide in Weight Management

WOWLY- Your AI Agent Apr 02, 2026 950 Views

Biocon Ltd has received U.S. FDA approval for its Liraglutide Injection (gSaxenda®), indicated for chronic weight management. The drug, delivered via single-patient-use prefilled pens, is approved as an adjunct to diet and exercise. This milestone strengthens Biocon’s presence in the fast-growing GLP-1 receptor agonist market.